Mechanistic Modeling Guides Bispecific Antibody Design and Target Selection for Maximizing Therapeutic Window Poster Mechanistic Modeling Guides Bispecific Antibody Design and Target Selection for Maximizing Therapeutic Window Therapeutic antibodies have shown promise in treating diseases such as cancer, but selectivity remains a…Danielle Pillsbury2025年3月28日
QSP Modeling Optimizes FIH Dose Selection for Multiple Myeloma Therapy Case Study QSPモデリングにより、多発性骨髄腫治療におけるFIH用量選択を最適化 Multiple myeloma, the second most common blood cancer, affects an estimated 160,000 individuals annually worldwide…Danielle Pillsbury2025年3月25日
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study Publication Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…Danielle Pillsbury2025年3月20日
Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach Publication Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach This study explores a model-based meta-analysis (MBMA) and a clinical utility index (CUI) approach to…Danielle Pillsbury2025年3月4日
Rare Oncology Product Launch Playbook: Universal Strategies for Success in the U.S. and Europe White Paper 希少な腫瘍領域製品の上市の手引き:米国および欧州で成功するための普遍的な戦略 Lorem ipsum dolor sit amet consectetur. At venenatis urna sapien ut lorem enim. Morbi lectus…Danielle Pillsbury2025年2月28日
Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies Publication 再発または難治性の骨髄線維症およびその他の骨髄系・固形腫瘍を対象としたNavtemadlinの集団薬物動態・薬力学解析 This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…Danielle Pillsbury2025年2月6日
Understanding Variability in CAR-T Cell Therapy Kinetics Publication Understanding Variability in CAR-T Cell Therapy Kinetics Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates…Danielle Pillsbury2025年1月23日
Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma Poster Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma Danielle Pillsbury2024年11月22日
A Pharmacokinetic Analysis of Drug Concentration Using a Novel Deep Learning Model Poster A Pharmacokinetic Analysis of Drug Concentration Using a Novel Deep Learning Model Danielle Pillsbury2024年11月22日
Model-Informed Drug Development Framework for the Development and Dose Optimization of Targeted Radiation Therapies Poster モデルを活かした医薬品開発(MIDD)の枠組みによる、標的放射線療法の開発と投与量の最適化 Danielle Pillsbury2024年11月22日